公开(公告)号：US20180170917A1

公开(公告)日：2018-06-21

申请号：US15510609

申请日：2015-09-11

Applicant: NOVARTIS AG

Inventor： Robert John AVERSA ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Thomas A. DINEEN, Jr. ,  Yan LOU ,  Gisele A. NISHIGUCHI ,  Savithri RAMURTHY ,  Alice C. RICO ,  Vivek RAUNIYAR ,  Martin SENDZIK ,  Sharadha SUBRAMANIAN ,  Lina Quattrocchio SETTI ,  Benjamin R. TAFT ,  Huw Rowland TANNER ,  Lifeng WAN

IPC: C07D405/14 ,  C07D405/12 ,  C07D305/06 ,  C07D413/14 ,  A61P35/00

CPC classification number: C07D405/14 ,  A61P35/00 ,  C07D305/06 ,  C07D405/12 ,  C07D413/14

Abstract: The present invention provides compounds of Formula (I) and (II) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent.

公开(公告)号：US20180362542A1

公开(公告)日：2018-12-20

申请号：US16062680

申请日：2016-12-14

Applicant: Novartis AG

Inventor： Robert John AVERSA ,  Matthew T. BURGER ,  Michael Patrick DILLON ,  Thomas A. DINEEN, Jr. ,  Rajesh KARKI ,  Savrithi RAMURTHY ,  Vivek RAUNIYAR ,  Richard ROBINSON ,  Patrick James SARVER

IPC: C07D498/04 ,  C07D491/044 ,  C07D487/04 ,  A61P35/00

CPC classification number: C07D498/04 ,  A61P35/00 ,  C07D487/04 ,  C07D491/04 ,  C07D491/044

Abstract: The present invention provides compounds of Formula (A): (I) as described herein, and salts thereof, and therapeutic uses of these compounds for treatment of disorders associated with Raf kinase activity. The invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds and a therapeutic co-agent, and methods of using the compositions and combinations to treat conditions including cancers.

公开(公告)号：US20190247392A1

公开(公告)日：2019-08-15

申请号：US16210968

申请日：2018-12-05

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/5355 ,  A61K31/4436 ,  A61K31/4433 ,  A61K31/44 ,  C07D403/06 ,  C07D401/12 ,  C07D401/06 ,  C07D213/73 ,  C07D413/14 ,  C07D241/20 ,  C07D401/04 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D498/04 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

公开(公告)号：US20180028532A1

公开(公告)日：2018-02-01

申请号：US15672568

申请日：2017-08-09

Applicant: Novartis AG

Inventor： Jeffrey T. BAGDANOFF ,  Yu DING ,  Wooseok HAN ,  Zilin HUANG ,  Qun JIANG ,  Xianming JIN ,  Xiang KOU ,  Patrick LEE ,  Mika LINDVALL ,  Zhongcheng MIN ,  Yue PAN ,  Sabina PECCHI ,  Keith Bruce PFISTER ,  Daniel POON ,  Vivek RAUNIYAR ,  Xiaojing Michael WANG ,  Qiong ZHANG ,  Jianguang ZHOU ,  Shejin ZHU

IPC: A61K31/497 ,  A61K31/4433 ,  A61K31/5355 ,  A61K31/44 ,  A61K31/4436

CPC classification number: A61K31/497 ,  A61K31/44 ,  A61K31/4433 ,  A61K31/4436 ,  A61K31/4439 ,  A61K31/4545 ,  A61K31/4965 ,  A61K31/506 ,  A61K31/5355 ,  A61K31/5377 ,  A61K31/5383 ,  A61K31/553 ,  A61K45/06 ,  A61K2121/00 ,  C07D213/73 ,  C07D241/20 ,  C07D401/04 ,  C07D401/06 ,  C07D401/12 ,  C07D403/06 ,  C07D405/04 ,  C07D405/14 ,  C07D409/04 ,  C07D413/14 ,  C07D498/04

Abstract: The present invention provides a compound of Formula (I) or a salt thereof; and therapeutic uses of these compounds. The present invention further provides pharmaceutical compositions comprising these compounds, and compositions comprising these compounds with a therapeutic co-agent.

公开(公告)号：US20240360137A1

公开(公告)日：2024-10-31

申请号：US18442235

申请日：2024-02-15

Applicant: Novartis AG

Inventor： Karin BRINER ,  Xin CHEN ,  Sajan JOSEPH ,  Vivek RAUNIYAR ,  Frédéric ZECRI

IPC: C07D487/04 ,  A61K31/519 ,  C07D519/00

CPC classification number: C07D487/04 ,  A61K31/519 ,  C07D519/00

Abstract: The invention relates to compounds which inhibit CDK2 (Cyclin-Dependent Kinase 2 or Cell Division protein Kinase 2), and to processes for the preparation of said compounds, pharmaceutical compositions comprising said compounds, and use of said compounds in the treatment of conditions, diseases and disorders mediated by CDK2.

公开(公告)号：US20240336598A1

公开(公告)日：2024-10-10

申请号：US18589841

申请日：2024-02-28

Applicant: Novartis AG

Inventor： Daniela ANGST ,  Philippe Bolduc ,  Matthew William Carson ,  Atwood Kim CHEUNG ,  Véronique Darsigny ,  Xiang GAO ,  Viktor HORNAK ,  Keith JENDZA ,  Rajesh KARKI ,  Ajay Kumar LAL ,  Gang LIU ,  Justin Yik Ching MAO ,  Jeffrey M. McKENNA ,  Erik MEREDITH ,  Muneto MOGI ,  Vivek RAUNIYAR ,  Liansheng SU ,  Ritesh TICHKULE ,  Shuangxi WANG ,  Chun ZHANG ,  Liang ZHAO ,  Rui ZHENG

IPC: C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

CPC classification number: C07D403/14 ,  A61K31/517 ,  A61K31/55 ,  A61K45/06 ,  C07D239/95 ,  C07D401/12 ,  C07D401/14

Abstract: The disclosure relates to a compound of Formula (I):




or a pharmaceutically acceptable salt thereof wherein A, Ra to Rd, and R4 to R7, are as described herein, as well as compositions and methods of using such compounds.